Stock Events

Rhythm Pharmaceuticals 

€42
0
+€0+0% Monday 15:19

Statistics

Day High
42
Day Low
41.2
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
2.67B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

22FebConfirmed
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-1
-0.9
-0.8
-0.7
Expected EPS
-0.7
Actual EPS
-0.7

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1RV.F. It's not an investment recommendation.

About

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Show more...
CEO
Dr. David P. Meeker M.D.
Employees
177
Country
US
ISIN
US76243J1051
WKN
000A2H5A0

Listings